Each year at this time, InBio has a companywide meeting to celebrate our “Highlights of the Year!” This year InBio had many reasons to celebrate, including achieving sustainability milestones, building new manufacturing space, and development of innovative products and services.

It has been a pleasure to work and collaborate with our clients this year. Thank you for your support. Here’s to a successful 2024!

Please find some of InBio’s 2023 highlights below:

InBio Green Benefits focuses on sustainability practices outside of the workplace and includes an annual employee stipend for sustainable purchases. In 2023, InBio Green Benefits has;

Achieved 5x of impact originally projected through the company spend of the Green Benefits program, which includes reimbursement on qualifying home energy, food and waste, and transportation expenses.

Recycled more than 418lbs of lab plastics since June.

Pursued installation of on-site EV chargers for employee EV’s.

InBio has expanded its ELISA 2.0 capabilities by building a new manufacturing facility, including a state-of-the-art Hamilton Vantage Liquid Handling System.

InBio’s new, streamlined manufacturing process is designed to deliver high quality and trusted ELISA 2.0 products for diagnostic and therapeutic applications. Through these process improvements, InBio continues the mission of helping researchers and companies with their critical allergen detection needs. Research made Real!

InBio has developed Apollo, a modern solution to simplify air sampling for the IAQ industry

Key Features of Apollo include:

• User-friendly; simple as plug and play
• Whisper quiet operation; under 40 decibels
• High flow rate sampler (>400Lmin)
• Long-duration sampling with defined flow rate; set it and forget it
• Improved allergen capture over IOMs and electrostatic dust collectors (EDC)
• Highly reproducible results

InBio’s Senior Scientist, Dr. Nicole Brackett, was the recipient of the Rosalind Franklin Society (RSF) Awards in Science. The annual award is for the best paper by a woman or under-represented minority in science in each of the publisher’s 100 peer-reviewed journals, providing role models and mentors for younger scientist following in their footsteps. Nicole’s research on applying CRISPR gene editing to delete Fel d 1 from cat cells has received global recognition.

InBio believes in transparency and continues to publish its  research findings in peer-reviewed journals. Recent publications include;

• Human monoclonal IgE antibodies-a major milestone in allergy. Curr Allergy Asthma Rep. 2023 Jan;23(1):53-65.

• Biological activity of human IgE monoclonal antibodies targeting Der p 2, Fel d 1, Ara h 2 in basophil mediator release assays. Front Immunol. 2023 May 9:14:1155613.

• Quantification of peanut allergens across recalled and nonrecalled lots of diagnostic peanut extracts. J Allergy Clin Immunol Pract. 2023 Jul 17:S2213-2198(23)00786-9.

• Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease. Front. Allergy 2023;4:1270326.

• Indoor Environmental Exposures and Their Relationship to Allergic Diseases. J Allergy Clin Immunol Pract. 2023 Oct; P2963-2970.

Find our complete list of publications here.

InBio held three webinars in 2023, including;

• Cleaning and Consumer Product Testing
• Molecular Allergy Diagnostics
• Food Allergy Extract Recalls and Diagnostics.

Find our complete list of webinars here.

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that’s exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialized needs.

• Broad product catalog
• Deep scientific background
• Ongoing commitment to R&D
• Well-documented subject-matter expertise
• Direct contact with our scientific team
• Flexible, collaborative relationships